KOR  ENG

앱클론 로고

Contact

AM105

am105

Bispecific antibody treatment for the simultaneous activation of
immune and anti-cancer cells

AM105 is a bispecific antibody derived from the AffiMab platform that specifically targets
EGFR disease protein and immune cells.

  • AM105
  • AM105 possesses a dual mechanism of action designed for tumor treatment.
    Its primary target is the CD137 (4-1BB) surface protein found on immune cells,
    while its secondary target is the EGFR disease protein. Notably, AM105 aims to
    mitigate toxicity by selectively activating immune cells in the vicinity of tumors.
    Additionally, its versatility allows for straightforward adaptation to address
    various cancers by substituting the target disease protein.
Designed by CHAIRONE
  • 앱클론 로고
  • AbClon Inc. #1401 285, Digital-ro, Guro-gu, Seoul, Republic of Korea
    T. +82-2109-1294
    F. +82-2109-1296
    E. abclon@abclon.com
About us
Overview CAR-T GMP History Collaboration Contact Us
Technology
CAR-T platform NEST platform AffiMab platform
Pipeline
AT101 AT501 AC101 AM201 AM105 AM109
Antibody Service
Antibody Service
IR/PR
News Stock IR Information
© AbClon. All rights reserved.